Barclays PLC Madrigal Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 40,279 shares of MDGL stock, worth $14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,279

Previous 40,279 -0.0%

Holding current value

$14 Million

Previous $8.55 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$212.22 - $292.96 $5.32 Million - $7.35 Million	25,083 Added 165.06%	40,279 $8.55 Million
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $1.94 Million - $2.93 Million	-10,027 Reduced 39.75%	15,196 $4.26 Million
Q1 2024 May 15, 2024	SELL	$171.37 - $283.23 $2.25 Million - $3.72 Million	-13,131 Reduced 34.24%	25,223 $6.74 Million
Q4 2023 Feb 15, 2024	BUY	$120.4 - $237.13 $1.44 Million - $2.83 Million	11,944 Added 45.23%	38,354 $8.87 Million
Q3 2023 Nov 07, 2023	SELL	$146.04 - $225.78 $84,849 - $131,178	-581 Reduced 2.15%	26,410 $3.86 Million
Q2 2023 Aug 03, 2023	SELL	$203.88 - $312.0 $5.78 Million - $8.84 Million	-28,344 Reduced 51.22%	26,991 $6.24 Million
Q1 2023 May 04, 2023	SELL	$231.06 - $307.08 $7.52 Million - $9.99 Million	-32,533 Reduced 37.02%	55,335 $13.4 Million
Q4 2022 Feb 13, 2023	BUY	$58.39 - $296.54 $2.6 Million - $13.2 Million	44,453 Added 102.39%	87,868 $25.5 Million
Q3 2022 Nov 03, 2022	BUY	$60.57 - $79.51 $2.17 Million - $2.84 Million	35,776 Added 468.33%	43,415 $2.82 Million
Q2 2022 Aug 12, 2022	SELL	$58.04 - $100.2 $97,275 - $167,935	-1,676 Reduced 17.99%	7,639 $547,000
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $297,949 - $543,175	-5,331 Reduced 36.4%	9,315 $914,000
Q4 2021 Feb 14, 2022	SELL	$72.34 - $95.09 $279,738 - $367,713	-3,867 Reduced 20.89%	14,646 $1.24 Million
Q3 2021 Nov 09, 2021	BUY	$78.35 - $105.02 $152,939 - $204,999	1,952 Added 11.79%	18,513 $1.48 Million
Q2 2021 Aug 13, 2021	SELL	$97.2 - $137.59 $253,400 - $358,697	-2,607 Reduced 13.6%	16,561 $1.61 Million
Q1 2021 May 13, 2021	BUY	$108.54 - $125.2 $340,707 - $393,002	3,139 Added 19.58%	19,168 $2.24 Million
Q4 2020 Feb 11, 2021	SELL	$110.06 - $133.7 $135,703 - $164,852	-1,233 Reduced 7.14%	16,029 $1.78 Million
Q3 2020 Nov 12, 2020	SELL	$99.78 - $124.21 $256,933 - $319,840	-2,575 Reduced 12.98%	17,262 $2.05 Million
Q2 2020 Aug 12, 2020	BUY	$60.13 - $125.71 $86,527 - $180,896	1,439 Added 7.82%	19,837 $2.25 Million
Q1 2020 May 13, 2020	BUY	$66.76 - $93.49 $344,081 - $481,847	5,154 Added 38.92%	18,398 $1.23 Million
Q4 2019 Feb 10, 2020	BUY	$84.28 - $118.5 $741,326 - $1.04 Million	8,796 Added 197.75%	13,244 $1.21 Million
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $50,049 - $63,172	-593 Reduced 11.76%	4,448 $383,000
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $154,283 - $241,252	1,693 Added 50.57%	5,041 $528,000
Q1 2019 May 15, 2019	BUY	$103.48 - $143.84 $346,244 - $481,288	3,346 Added 167300.0%	3,348 $419,000
Q4 2018 Feb 14, 2019	SELL	$94.77 - $215.54 $893,491 - $2.03 Million	-9,428 Reduced 99.98%	2 $0
Q3 2018 Nov 14, 2018	SELL	$207.3 - $300.31 $2.18 Million - $3.16 Million	-10,516 Reduced 52.72%	9,430 $2.02 Million
Q2 2018 Aug 14, 2018	SELL	$101.55 - $313.9 $1.29 Million - $3.99 Million	-12,724 Reduced 38.95%	19,946 $5.58 Million
Q1 2018 May 15, 2018	BUY	$93.35 - $149.04 $2.92 Million - $4.67 Million	31,305 Added 2293.41%	32,670 $3.82 Million
Q4 2017 Feb 14, 2018	BUY	$39.35 - $97.37 $49,895 - $123,465	1,268 Added 1307.22%	1,365 $125,000
Q3 2017 Nov 14, 2017	BUY	$15.48 - $46.19 $1,501 - $4,480	97	97 $4,000

Others Institutions Holding MDGL

# of Institutions

296

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account